Full Press Release Details
ordspono odronextamab approved in the european union for the treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma.
REGN
ordspono odronextamab approved in the european union for the treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma
Key Takeaway: ordspono odronextamab approved in the european union for the treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma